WILLOW GROVE, PA — ECRI and Institute for Safe Medication Practices warned that many compounded peptide products marketed for wellness and anti-aging purposes lack sufficient clinical evidence supporting their safety or effectiveness as consumer demand for the products expands rapidly.
The organizations released a joint white paper arguing that the commercial market for compounded peptides has advanced well beyond available human clinical research, particularly for products promoted for muscle growth, injury recovery, immune support, and anti-aging treatments.
The report specifically identified compounds including BPC-157, TB-500, Melanotan II, and epitalon, noting that many are not approved by the U.S. Food and Drug Administration for human use.
According to the paper, recent regulatory changes affecting 12 peptide compounds in April 2026 were not accompanied by new clinical evidence and should not be interpreted as confirmation of safety or efficacy.
The organizations cited significant evidence gaps surrounding BPC-157, one of the most widely marketed peptide products.
The report stated that 35 of 36 published studies involving BPC-157 were conducted in animals and that no published Phase 1 human safety studies or controlled human efficacy trials currently exist.
Researchers also cited testing of peptide products sold through unregulated online markets that found purity levels ranging from 5% to 75%, including samples containing arsenic and lead concentrations above established toxicity limits for injectable drugs.
The paper also referenced reported safety concerns involving the broader peptide category, including a halted clinical trial following a fatal cardiac event, case reports involving melanoma and kidney dysfunction, and at least one reported death tied to intravenous administration.
Rita Jew indicated consumer interest in compounded peptides has accelerated despite limited scientific validation.
“Patients are injecting substances that have never been adequately tested in humans, based on marketing claims the available evidence simply does not support,” Jew said in a statement.
The organizations also warned that many consumers obtain peptide products through online sellers marketing them as “research use only” substances without prescription requirements, pharmacist oversight, or verified quality testing.
ECRI and ISMP recommended that consumers consult licensed medical professionals before considering peptide therapies and use only FDA-approved products obtained through regulated pharmacies.
The full report is available through ECRI White Paper on Compounded Peptides.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.